WO1994004541A3 - Protein kinase inhibitors and related compounds combined with taxol - Google Patents

Protein kinase inhibitors and related compounds combined with taxol Download PDF

Info

Publication number
WO1994004541A3
WO1994004541A3 PCT/US1993/007054 US9307054W WO9404541A3 WO 1994004541 A3 WO1994004541 A3 WO 1994004541A3 US 9307054 W US9307054 W US 9307054W WO 9404541 A3 WO9404541 A3 WO 9404541A3
Authority
WO
WIPO (PCT)
Prior art keywords
taxol
protein kinase
kinase inhibitors
related compounds
compounds
Prior art date
Application number
PCT/US1993/007054
Other languages
French (fr)
Other versions
WO1994004541A2 (en
Inventor
Irene Abraham
Paul A Aristoff
Harvey I Skulnick
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to JP6506283A priority Critical patent/JPH08500112A/en
Priority to KR1019950700489A priority patent/KR950702994A/en
Priority to EP93918422A priority patent/EP0655066A1/en
Priority to AU47876/93A priority patent/AU4787693A/en
Publication of WO1994004541A2 publication Critical patent/WO1994004541A2/en
Publication of WO1994004541A3 publication Critical patent/WO1994004541A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

This invention describes both known and novel compounds, some of which are protein kinase inhibitors, that may be combined with taxol type compounds. The combination of disclosed compounds plus taxol type compounds exhibits powerful synergistic effects and the combinations are useful in the treatment of cancer. The novel compounds and their synthesis are described. A compound of formula (I), above, is described wherein R1-R8 represent various substituents.
PCT/US1993/007054 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds combined with taxol WO1994004541A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6506283A JPH08500112A (en) 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds in combination with taxol
KR1019950700489A KR950702994A (en) 1992-08-12 1993-07-30 PROTEIN KINASE INHIBITORS AND RELATED COMPOUNDS COMBINED WITH TAXOL
EP93918422A EP0655066A1 (en) 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds combined with taxol
AU47876/93A AU4787693A (en) 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds combined with taxol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92919992A 1992-08-12 1992-08-12
US07/929,199 1992-08-12

Publications (2)

Publication Number Publication Date
WO1994004541A2 WO1994004541A2 (en) 1994-03-03
WO1994004541A3 true WO1994004541A3 (en) 1994-06-09

Family

ID=25457472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007054 WO1994004541A2 (en) 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds combined with taxol

Country Status (6)

Country Link
EP (1) EP0655066A1 (en)
JP (1) JPH08500112A (en)
KR (1) KR950702994A (en)
AU (1) AU4787693A (en)
CA (1) CA2140653A1 (en)
WO (1) WO1994004541A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
AU715527B2 (en) * 1995-06-27 2000-02-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
US5900429A (en) * 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
AU758241B2 (en) * 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6235776B1 (en) * 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
ATE556713T1 (en) 1999-01-13 2012-05-15 Bayer Healthcare Llc OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7820718B1 (en) * 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
GB9915069D0 (en) * 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
WO2001010440A1 (en) * 1999-08-09 2001-02-15 Trustees Of Dartmouth College COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6548531B2 (en) * 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
WO2004026319A2 (en) * 2002-09-17 2004-04-01 Centre National De La Recherche Scientifique Pharmaceutical compositions increasing camp useful for the treatment of cancers
PT1636585E (en) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diaryl ureas with kinase inhibiting activity
AU2003250150A1 (en) * 2003-07-23 2005-02-25 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation
CA2479696A1 (en) 2003-11-11 2005-05-11 Amadeo Parissenti Use of calphostin-c to treat drug-sensitive tumor cells
WO2007017497A2 (en) * 2005-08-09 2007-02-15 Johannes Gutenberg-Universität Mainz Staurosporine derivatives for treating non-small cell lung cancer
KR102271848B1 (en) * 2013-11-01 2021-07-01 피트니 파마슈티컬스 피티와이 리미티드 Pharmaceutical combinations for the treatment of cancer
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (en) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd Physiologically active substance k-252 derivative
JPS63295589A (en) * 1987-01-22 1988-12-01 Kyowa Hakko Kogyo Co Ltd Derivative of physiologically active substance k-252
EP0303697A1 (en) * 1987-03-09 1989-02-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
EP0323171A2 (en) * 1987-12-24 1989-07-05 Kyowa Hakko Kogyo Co., Ltd. Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (en) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd Physiologically active substance k-252 derivative
JPS63295589A (en) * 1987-01-22 1988-12-01 Kyowa Hakko Kogyo Co Ltd Derivative of physiologically active substance k-252
EP0303697A1 (en) * 1987-03-09 1989-02-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
EP0323171A2 (en) * 1987-12-24 1989-07-05 Kyowa Hakko Kogyo Co., Ltd. Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER CHEMOTHER. PHARMACOL., vol. 15, no. 1, 1985, pages 16 - 19 *
CHEMICAL ABSTRACTS, vol. 103, no. 21, 25 November 1985, Columbus, Ohio, US; abstract no. 171551e, T. TSURUO ET AL: "Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns" page 29; *
CHEMICAL ABSTRACTS, vol. 107, no. 25, 21 December 1987, Columbus, Ohio, US; abstract no. 236750y, T. HIRATA ET AL: "Preparation of k-252 derivatives as protein kinase C inhibitors and drugs" page 796; *
CHEMICAL ABSTRACTS, vol. 111, no. 21, 20 November 1989, Columbus, Ohio, US; abstract no. 194456g, T. HIRATA ET AL: "Preparation of K-252 derivatives as protein kinase C inhibitors and formulations containing them" page 743; *
R. L. FINE ET AL: "Phorbol esters induce multidrug resistance in human breast cancer cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, no. 2, January 1988 (1988-01-01), WASHINGTON US, pages 582 - 586 *

Also Published As

Publication number Publication date
KR950702994A (en) 1995-08-23
CA2140653A1 (en) 1994-03-03
EP0655066A1 (en) 1995-05-31
WO1994004541A2 (en) 1994-03-03
AU4787693A (en) 1994-03-15
JPH08500112A (en) 1996-01-09

Similar Documents

Publication Publication Date Title
WO1994004541A3 (en) Protein kinase inhibitors and related compounds combined with taxol
MX9601360A (en) Synergistic stabilizing mixture.
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
CA2210258A1 (en) Substituted oxazolidine calpain and/or cathepsin b inhibitors
WO1999054326A8 (en) Dihydropyrimidines
BG106585A (en) Kinase inhibitors as therapeutic agents
PL304649A1 (en) Novel derivatives of taxane and pharmaceutical agents
IL116078A0 (en) Substituted heterocyclic compounds capable of inhibiting serine proteases
CY2543B1 (en) 9-Ä(Substituted glycyl)amidoÜ-6-(substituted)-5-hydroxy-6-deoxytetracyclines
AP9901478A0 (en) Compounds for the treatment of ischemia.
BG105784A (en) Triazole compounds with dopamine-d3-receptor affinity
MX9700557A (en) Dihydrobenzofuranes.
UA39099C2 (en) Cyclic nitrogen-containing derivatives, mixture of isomers thereof or separate isomers or salts thereof
HK1026909A1 (en) Substituted phenyl derivatives, their preparation and use
IL148544A0 (en) Tyrosine derivatives
CA2080705A1 (en) Substituted pyrimidines
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
DK0705100T3 (en) Therapeutically substituted guanidines
CA2214131A1 (en) Trisubstituted phenyl derivatives
WO1998036730A3 (en) Compositions for treating acne rosacea
DE69907419D1 (en) Antitumorwirkstoffe
CA2264063A1 (en) Cryptophycin compounds
AU7000094A (en) Indolocarbazole compound useful as proteinkinase c inhibitor
MY109602A (en) Heteroatoms-containing tricyclic compounds
CA2116829A1 (en) Use of a pregnane derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1993918422

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2140653

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1993918422

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1993918422

Country of ref document: EP